BACAINN THERAPEUTICS

bacainn-therapeutics-logo

Bacainn creates cutting-edge medicines that target the innate immune system to combat uncontrolled inflammation.

#SimilarOrganizations #Website #More

BACAINN THERAPEUTICS

Social Links:

Industry:
Health Care Health Diagnostics Professional Services Therapeutics Wellness

Founded:
2017-01-01

Address:
Concord, Massachusetts, United States

Country:
United States

Website Url:
http://www.bacainntherapeutics.com

Total Employee:
1+

Status:
Active

Email Addresses:
[email protected]

Technology used in webpage:
SPF IPv6 Cloudflare Hosting Person Schema Microsoft Exchange Online Office 365 Mail Gravatar Profiles Microsoft Azure DNS Cloudflare DNS GoDaddy Verification


Similar Organizations

la-vista-chiropractic-wellness-center-logo

la vista chiropractic & wellness center

la vista chiropractic & wellness center is a healthcare industry.

proseries-logo

ProSeries

ProSeries manufactures athletic equipment and cold therapy since wrap products that are custom made to control pain and inflamation.

spa-utopia-logo

Spa Utopia

Spa Utopia is a health and wellness center that offers a variety of therapies, treatments, and retail products.

Official Site Inspections

http://www.bacainntherapeutics.com

  • Host name: 172.67.217.83
  • IP address: 172.67.217.83
  • Location: United States
  • Latitude: 37.751
  • Longitude: -97.822
  • Timezone: America/Chicago

Loading ...

More informations about "Bacainn Therapeutics"

Bacainn Therapeutics - Crunchbase Company Profile & Funding

Organization. Bacainn Therapeutics . Connect to CRM . Save . Summary. People. Technology. Signals & News. Similar Companies. About. Bacainn creates cutting-edge medicines that โ€ฆSee details»

Bacainn Therapeutics: Revenue, Worth, Valuation & Competitors โ€ฆ

Bacainn Therapeutics is a Biotech related company founded in 2017 and based in Massachusetts with an estimated revenue of $1.9M, and 12 employees. It has 10 competitors including โ€ฆSee details»

Bacainn Therapeutics 2025 Company Profile: Valuation, โ€ฆ

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations; US-20240277798-A1: Cyclosporine compositions and methods of use: PendingSee details»

Bacainn Therapeutics - VentureRadar

Similar Companies: Adiso Therapeutics USA Privately Held Adiso is a pharmaceutical company that develops innovative medicines to treat inflammatory diseases. Their therapeutic approach โ€ฆSee details»

Bacainn Therapeutics - Overview, News & Similar companies

Jul 9, 2021 Bacainn Therapeutics contact info: Phone number: (781) 290-9076 Website: www.bacainntherapeutics.com What does Bacainn Therapeutics do? Bacainn Therapeutics is โ€ฆSee details»

Bacainn Therapeutics Overview | SignalHire Company Profile

Organization Website: bacainntherapeutics.com : Social Links: Bacainn Therapeutics industries Biotech: Headquarters Location: Greater ... 1-10 employees: Founded: 2017: Bacainn โ€ฆSee details»

Bacainn Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...

Jul 5, 2023 Explore Bacainn Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 1 news, Drug:BT-051.See details»

Bacainn Therapeutics Inc - Drug pipelines, Patents, Clinical

Explore Bacainn Therapeutics Inc with its drug pipeline, therapeutic area, technology platform, , Disease Domain:Immune System Diseases, Technology Platform:Small molecule drug, โ€ฆSee details»

Bacainn Therapeutics, Inc.:Company Profile & Technical Research ...

Bacainn Therapeutics is a company that provides Innate immune system, Inflammation and more. Bacainn Therapeutics is headquartered in United States Massachusetts. Bacainn โ€ฆSee details»

Bacainn Therapeutics Inc. - BioCentury Company Profiles - BCIQ

Bacainn Therapeutics Inc. - BioCentury Company Profiles for the biopharma industrySee details»

Bacainn Therapeutics Reports Positive Data from โ€ฆ

Dec 3, 2020 The organization reported the fruitful consummation of the first-in-human preliminary a. Drug Name: BT-051 Bacainn Therapeutics has announced positive outcomes from the Phase I clinical ...See details»

Bacainn Therapeutics | VentureRadar

Find out more about Bacainn Therapeutics, inflammation, Proprietary Compounds and neutrophils. All; Ranked; Organisation Names; Apps and Links. Homepage (myVR) Funding โ€ฆSee details»

Bacainn Therapeutics: Revenue, Competitors, Alternatives

Bacainn Therapeutics 's estimated revenue per employee is $ 155,000Employee Data. Bacainn Therapeutics has 12 Employees. Bacainn Therapeutics; grew their employee count by -20%. โ€ฆSee details»

Bacainn Therapeutics Announces IND Clearance for BT051 and

Jun 9, 2020 CONCORD, Mass.--(BUSINESS WIRE)-- Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, announced today FDAโ€™s โ€ฆSee details»

Bacainn Therapeutics Reports Positive Topline Results from Phase โ€ฆ

CONCORD, Mass. โ€” Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, today announced thesuccessful completion of the โ€ฆSee details»

Bacainn Therapeutics Presents at ECCO โ€˜21 Results ... - Business Wire

Jul 9, 2021 Bacainn Therapeutics Presents at ECCO โ€˜21 Results from Phase 1 Study that Shows BT051, an Oral, Locally-Acting Inhibitor of Neutrophil Trafficking and Activity, Is Safe โ€ฆSee details»

Bacainn Therapeutics - VentureRadar

Bacainn approaches inflammation differently in gastrointestinal and respiratory diseases. In exploring novel approaches for ulcerative colitis,... ... Find out more ...See details»

Bacainn Therapeutics Reports Positive Topline Results from Phase โ€ฆ

Dec 2, 2020 Bacainn Therapeutics was founded based on the extensive insights into neutrophil biology generated by Dr. Beth McCormickโ€™s laboratory at the University of Massachusetts โ€ฆSee details»

Bacainn Therapeutics reports positive data from ulcerative colitis trial

Dec 3, 2020 Bacainn Therapeutics has reported positive results from the Phase I clinical trial of gut-restricted drug, BT051, for treating inflammatory diseases such as ulcerative colitis. The โ€ฆSee details»

Bacainn Therapeutics Presents at ECCO โ€˜21 Results from

Jul 9, 2021 Bacainn Therapeutics, Inc. today presented results at the European Crohnโ€™s and Colitis Organisationโ€™s 2021 Virtual Congress from a Phase 1 study that showed its lead asset โ€ฆSee details»

linkstock.net © 2022. All rights reserved